Aspen Pharmacare said it had secured regulatory approval to market Eli Lilly's blockbuster diabetes and obesity drug, ...

Apple's strong Services growth, Eli Lilly's GLP-1 momentum, and Visa's digital expansion headline today's top stock reports.

Explore Eli Lilly’s role in Healthcare Stocks, S&P 500 companies, and its impact on market trends and the S&P 500 index.

Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s ...

Fundamentally, Eli Lilly represents a juggernaut in medical innovations. Recently, the company has taken a leadership role in ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

South Africa's Aspen Pharmacare said on Monday it had secured regulatory approval to market Eli Lilly's blockbuster diabetes ...

During periods of economic uncertainty, investing in pharmaceutical companies demonstrates unique defensive characteristics.

Lilly’s legal offensive against compounders of its popular weight loss drugs hits another snag in court.

Almost 2.5 million people in Britain ordered weight-loss jabs in July, according to new estimates. However, a big price hike introduced in September may have seen some turn away from Mounjaro, dubbed ...

Eli Lilly LLY and AbbVie ABBV are large, well-established U.S. pharmaceutical companies, boasting several blockbuster drugs, ...

North Carolina's State Health Plan stopped providing coverage for GLP-1s for weight loss last year. A new agreement with CVS ...